Literature DB >> 26903267

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

D R Goldsmith1, M H Rapaport1, B J Miller2.   

Abstract

Schizophrenia, bipolar disorder and major depressive disorder (MDD) have all been associated with aberrant blood cytokine levels; however, neither the pattern of cytokine alterations nor the impact of clinical status have been compared across disorders. We performed a meta-analysis of blood cytokines in acutely and chronically ill patients with these major psychiatric disorders. Articles were identified by searching the PubMed, PsycInfo and Web of Science, and the reference lists of these studies. Sixty-eight studies met the inclusion criteria (40 schizophrenia, 10 bipolar disorder and 18 MDD) for acutely ill patients. Forty-six studies met the inclusion criteria (18 schizophrenia, 16 bipolar disorder and 12 MDD) for chronically ill patients. Levels of two cytokines (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)), one soluble cytokine receptor (sIL-2R), and one cytokine receptor antagonist (IL-1RA) were significantly increased in acutely ill patients with schizophrenia, bipolar mania and MDD compared with controls (P<0.01). Following treatment of the acute illness, IL-6 levels significantly decreased in both schizophrenia and MDD (P<0.01); sIL-2R levels increased in schizophrenia; and IL-1RA levels in bipolar mania decreased. In chronically ill patients, the levels of IL-6 were significantly increased in schizophrenia, euthymic (but not depressed) bipolar disorder and MDD compared with controls (P<0.01). The levels of IL-1β and sIL-2R were significantly increased in both chronic schizophrenia and euthymic bipolar disorder. Overall, there were similarities in the pattern of cytokine alterations in schizophrenia, bipolar disorder and MDD during acute and chronic phases of illness, raising the possibility of common underlying pathways for immune dysfunction. Effects of treatment on cytokines were more robust for schizophrenia and MDD, but were more frequently studied than for acute mania. These findings have important implications for our understanding of the pathophysiology and treatment of major psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903267      PMCID: PMC6056174          DOI: 10.1038/mp.2016.3

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  161 in total

1.  Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.

Authors:  M Kubera; G Kenis; E Bosmans; A Zieba; D Dudek; G Nowak; M Maes
Journal:  Pol J Pharmacol       Date:  2000 May-Jun

2.  Increased levels of adipokines in bipolar disorder.

Authors:  Izabela Guimarães Barbosa; Natalia Pessoa Rocha; Aline Silva de Miranda; Pedro Vieira da Silva Magalhães; Rodrigo Barreto Huguet; Lirlandia Pires de Souza; Flávio Kapczinski; Antonio Lucio Teixeira
Journal:  J Psychiatr Res       Date:  2011-12-03       Impact factor: 4.791

3.  Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia.

Authors:  Haibo Liu; Yimin Kang; Jun Liang; Cunbao Li; Meihong Xiu; Dachun Chen; Fude Yang; Fang Wang; Guiying Wu; Colin N Haile; Therese A Kosten; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychiatry Res       Date:  2012-03-13       Impact factor: 3.222

4.  Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia.

Authors:  Bojana Dunjic-Kostic; Miroslava Jasovic-Gasic; Maja Ivkovic; Nevena V Radonjic; Maja Pantovic; Aleksandar Damjanovic; Sanja Totic Poznanovic; Aleksandar Jovanovic; Tatjana Nikolic; Natasa D Petronijevic
Journal:  Psychiatr Danub       Date:  2013-03       Impact factor: 1.063

5.  Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia.

Authors:  Cristiano Noto; Ary Gadelha; Síntia I Belangero; Letícia M Spindola; Natália Pessoa Rocha; Aline Silva de Miranda; Antônio Lúcio Teixeira; Marília Arruda Cardoso Smith; Jair de Jesus Mari; Rodrigo Affonseca Bressan; Elisa Brietzke
Journal:  J Psychiatr Res       Date:  2013-01-26       Impact factor: 4.791

6.  A detailed examination of cytokine abnormalities in Major Depressive Disorder.

Authors:  N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-03       Impact factor: 4.600

7.  Plasma levels of soluble transferrin receptors and Clara cell protein (CC16) during bipolar mania and subsequent remission.

Authors:  Shang-Ying Tsai; Hsin-Chien Lee; Chiao-Chicy Chen; Chao-Hsien Lee
Journal:  J Psychiatr Res       Date:  2003 May-Jun       Impact factor: 4.791

8.  Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine.

Authors:  Jari-Pekka Klemettilä; Olli Kampman; Niko Seppälä; Merja Viikki; Mari Hämäläinen; Eeva Moilanen; Esa Leinonen
Journal:  Psychiatry Res       Date:  2014-05-09       Impact factor: 3.222

Review 9.  Regulation of macrophage biology by lithium: a new look at an old drug.

Authors:  Pongali B Raghavendra; Eunhee Lee; Narayanan Parameswaran
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-27       Impact factor: 4.147

10.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.

Authors:  Wilco de Jager; Katarzyna Bourcier; Ger T Rijkers; Berent J Prakken; Vicki Seyfert-Margolis
Journal:  BMC Immunol       Date:  2009-09-28       Impact factor: 3.615

View more
  361 in total

1.  Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior.

Authors:  Elisabeth G Vichaya; Phillip S Gross; Darlene J Estrada; Steve W Cole; Aaron J Grossberg; Scott E Evans; Michael J Tuvim; Burton F Dickey; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

Review 2.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

Review 3.  Treatment failure in inflammatory arthritis: time to think about syndemics?

Authors:  Elena Nikiphorou; Heidi Lempp; Brandon A Kohrt
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

4.  Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function.

Authors:  Sophia Kogan; Luz H Ospina; David Kimhy
Journal:  Brain Behav Immun       Date:  2018-09-12       Impact factor: 7.217

Review 5.  Interoception and Inflammation in Psychiatric Disorders.

Authors:  Jonathan Savitz; Neil A Harrison
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-01-09

6.  Insomnia and suicidal ideation in nonaffective psychosis.

Authors:  Brian J Miller; Carmen B Parker; Mark H Rapaport; Peter F Buckley; William V McCall
Journal:  Sleep       Date:  2019-02-01       Impact factor: 5.849

Review 7.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

8.  Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms.

Authors:  Senthil Kumaran Satyanarayanan; Yin-Hwa Shih; Yu-Chuan Chien; Shih-Yi Huang; Piotr Gałecki; Siegfried Kasper; Jane Pei-Chen Chang; Kuan-Pin Su
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

9.  Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Authors:  Suat Kucukgoncu; Urska Kosir; Elton Zhou; Erin Sullivan; Vinod H Srihari; Cenk Tek
Journal:  Early Interv Psychiatry       Date:  2018-10-02       Impact factor: 2.732

Review 10.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.